198 related articles for article (PubMed ID: 36653312)
1. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma.
Su Y; Zhang Z; Lee LTO; Peng L; Lu L; He X; Zhang X
Adv Healthc Mater; 2023 Jan; 12(6):e2202663. PubMed ID: 36653312
[TBL] [Abstract][Full Text] [Related]
2. Co-Delivery of siNRF2 and Sorafenib by a "Click" Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma.
Tong R; Feng X; Sun J; Ling Z; Wang J; Li S; Yang B; Deng J; He G; Wu J
Small; 2024 May; 20(21):e2307273. PubMed ID: 38102096
[TBL] [Abstract][Full Text] [Related]
3. Tumor Microenvironment-Responsive, Multistaged Liposome Induces Apoptosis and Ferroptosis by Amplifying Oxidative Stress for Enhanced Cancer Therapy.
Kou L; Sun R; Jiang X; Lin X; Huang H; Bao S; Zhang Y; Li C; Chen R; Yao Q
ACS Appl Mater Interfaces; 2020 Jul; 12(27):30031-30043. PubMed ID: 32459093
[TBL] [Abstract][Full Text] [Related]
4. pH-activated nanoplatform for visualized photodynamic and ferroptosis synergistic therapy of tumors.
Sun R; Ma W; Ling M; Tang C; Zhong M; Dai J; Zhu M; Cai X; Li G; Xu Q; Tang L; Yu Z; Peng Z
J Control Release; 2022 Oct; 350():525-537. PubMed ID: 36055597
[TBL] [Abstract][Full Text] [Related]
5. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma.
Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
7. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy.
Huang L; Xu R; Li W; Lv L; Lin C; Yang X; Yao Y; Saw PE; Xu X
Acta Biomater; 2023 May; 162():98-109. PubMed ID: 36931417
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of sorafenib and VEGF-siRNA via pH-sensitive liposomes for the synergistic treatment of hepatocellular carcinoma.
Yao Y; Wang T; Liu Y; Zhang N
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1374-1383. PubMed ID: 30977418
[TBL] [Abstract][Full Text] [Related]
9. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis.
Li Y; Yang W; Zheng Y; Dai W; Ji J; Wu L; Cheng Z; Zhang J; Li J; Xu X; Wu J; Yang M; Feng J; Guo C
J Exp Clin Cancer Res; 2023 Jan; 42(1):6. PubMed ID: 36604718
[TBL] [Abstract][Full Text] [Related]
10. Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy.
Yu Y; Shen X; Xiao X; Li L; Huang Y
Small; 2023 Sep; 19(36):e2301149. PubMed ID: 37165608
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional metal-coordinated Co-assembled carrier-free nanoplatform based on dual-drugs for ferroptosis-mediated cocktail therapy of hepatocellular carcinoma growth and metastasis.
Zhao RR; Wu JH; Tong LW; Li JY; Lu YS; Shao JW
J Colloid Interface Sci; 2024 Apr; 660():257-276. PubMed ID: 38244494
[TBL] [Abstract][Full Text] [Related]
12. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
13. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma.
Wang Z; Zhou C; Zhang Y; Tian X; Wang H; Wu J; Jiang S
Biomed Pharmacother; 2024 Jan; 170():116074. PubMed ID: 38147732
[TBL] [Abstract][Full Text] [Related]
14. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells.
Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W
Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528
[TBL] [Abstract][Full Text] [Related]
15. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
[TBL] [Abstract][Full Text] [Related]
16. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
17. Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy.
Yuan Y; Tian C; Wang Q; Qiu X; Wang Y; Jiang H; Hao J; He Y
Adv Healthc Mater; 2023 Nov; 12(28):e2301292. PubMed ID: 37458333
[TBL] [Abstract][Full Text] [Related]
18. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N
Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597
[TBL] [Abstract][Full Text] [Related]
19. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
[TBL] [Abstract][Full Text] [Related]
20. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase.
Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N
Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
